Combination therapy of lapatinib, an EGFR and HER-2 inhibitor, and capecitabine, a third-generation aromatase inhibitor (AI), showed a tolerable regimen for patients with gemcitabine-refractory pancreatic cancer [64]. Here, ERBB2 is linked to pancreatic neoplasm.